Signal transduction and targeted therapy · 2022
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Tianhong, Lu Shuaiyao, He Zhanlong, Liu Hongqi, Wang Junbin, Tang Cong, Yang Ting, Yu Wenhai, Li Hua, Yang Yun, Yang Hao, Yue Lei, Zhou Yanan, Yang Fengmei, Luo Zhiwu, Li Yanyan, Xiang Hong, Zhao Yuan, Wang Jie, Wang Haixuan, Long Runxiang, Kuang Dexuan, Tan Wenjie, Peng Xiaozhong, Li Qihan, Xie Zhongping
Аннотация
Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2. To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants, we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine, followed by challenging with emerging SARS-CoV-2 variants of concern (VOCs). These vaccinated animals produced neutralizing antibodies against Alpha, Beta, Delta, and Omicron variants, although there were certain declinations of geometric mean titer (GMT) as compared with prototypic SARS-CoV-2. Of note, in vivo this prototypic vaccine not only reduced the viral loads in nasal, throat and anal swabs, pulmonary tissues, but also improved the pathological changes in the lung infected by variants of Alpha, Beta, and Delta. In summary, the prototypic SARS-CoV-2 inactivated vaccine in this study protected against VOCs to certain extension, which is of great significance for prevention and control of COVID-19.